Testing erugliflozin for fatty liver and diabetes control
Treatments studied
Part of Digestive system clinical trials.
This trial studies whether erugliflozin can reduce liver fat and liver scarring (fibrosis) while also improving blood sugar in people with type 2 diabetes and fatty liver disease (NASH/NAFLD). It’s designed for people who haven’t used certain diabetes medicines like SGLT2 inhibitors or insulin before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign a written consent form and are willing to join the study
- You’re between 18 and 65 years old
- You have type 2 diabetes and you have not used insulin or SGLT2 inhibitor medicines before
- Your body mass index (BMI) is over 23
- Your blood sugar marker (HbA1c) is between 6.5% and 10%
- Your ultrasound shows fatty liver (liver steatosis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
This study tests whether a medicine called henagliflozin can help reduce fat in the liver for people with type 2 diabetes and non-alcoholic fatty liver disease. It may help improve liver health and blood sugar control at the same time.
This study tests a medication called empagliflozin (a type of SGLT2 inhibitor) to see if it can help treat fatty liver disease in teenagers and young adults. It may improve liver health and help with weight management.
This study tests whether SGLT2 inhibitors, a type of diabetes medication, can help reduce fat buildup in the liver (NAFLD) for people with type 2 diabetes who also have moderate kidney problems (stage 3 or 4 CKD). It may offer a new way to treat both conditions together.
This trial studies whether an SGLT2 medicine can improve non-alcoholic fatty liver disease (fatty liver not caused by alcohol) in teens with obesity. It may help lower liver fat or liver irritation, alongside usual lifestyle changes.
This Phase 2 trial studies whether the medication ertugliflozin can help people with chronic heart failure. You would be asked to follow a set treatment plan and complete repeated urine (and other) testing to see how your body responds.
Hear when a new Liver Fat trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.